Vertex Pharmaceuticals Could See Strong Gains From Incivek
by | Posted 4.10.2012 | Post Comment (No Comments)

Vertex Pharmaceuticals (VRTX) is looking to be a big frontrunner in the biotech industry. With the development and mildly successful testing of Vertex’s next big drug, Incivek, there is great potential for Vertex to be a major competitor against big names such as Dendreon (DNDN).

Read the rest of this post @ DividendKings